Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688105 liabilities breakdown for a breakdown of total debt and financial obligations.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Luye Pharma Group Ltd
F:LUP
|
0.021x |
|
Hnac Technology Co Ltd
SHE:300490
|
0.023x |
|
Shanghai Hugong Elec(Group)
SHG:603131
|
0.000x |
|
RITES Limited
NSE:RITES
|
-0.030x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
Ramsay Generale De Sante
PA:GDS
|
0.060x |
|
Johnson Health Tech Co Ltd
TW:1736
|
-0.003x |
|
Ami Organics Limited
NSE:AMIORG
|
0.006x |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Nanjing Vazyme Biotech Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
CN¥-9.68 Million ≈ $-1.42 Million |
-0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
CN¥198.40 Million ≈ $29.03 Million |
0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
CN¥735.17 Million ≈ $107.58 Million |
0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
CN¥616.80 Million ≈ $90.26 Million |
0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
CN¥803.55 Million ≈ $117.59 Million |
0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
CN¥15.20 Million ≈ $2.22 Million |
0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
CN¥-4.00 Million ≈ $-585.21K |
-0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
CN¥-3.86 Million ≈ $-564.87K |
-0.026x | -- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more